Drug Profile
CLR 3001
Alternative Names: CLR3001Latest Information Update: 27 Aug 2019
Price :
$50
*
At a glance
- Originator Clera
- Class Antidementias; Antidepressants; Small molecules
- Mechanism of Action Dopamine receptor modulators; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Cognition disorders; Major depressive disorder
Most Recent Events
- 27 Aug 2019 Discontinued - Phase-II for Cognition disorders in Canada (PO)
- 12 Feb 2016 CLR 3001 is still in phase IIa trial for Cognition disorder in Canada (Clera pipeline, February 2016)
- 21 Jan 2014 CLR 3001 is available for licensing as of 01 Jan 2014. http://www.clera.com